A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
Rupa NarayanTraci M BlonquistAshkan EmadiRobert P HasserjianMeghan BurkeChristopher LescinskasDonna S NeubergAndrew M BrunnerGabriela HobbsHanno HockSteven L McAfeeYi-Bin ChenEyal AttarTimothy A GraubertChristina BertoliJenna A MoranMeghan K BergeronJulia E FosterAura Y RamosTina T SomMegan K VartanianJennifer L StoryKristin McGregorMolly MacraeTanya BehnanMargaret C WeyJessica RaeFrederic I PrefferPatricia LeshoVu H DuongMason L MannKaren K BallenChristine ConnollyPhilip C AmreinAmir T FathiPublished in: Cancer (2019)
The outcomes for patients with relapsed/refractory acute myeloid leukemia (R/R AML) are exceptionally poor. New and emerging treatment combinations are actively being studied in an effort to improve outcomes. The authors examined the combination of brentuximab vedotin, an antibody product that recognizes a marker called CD30, with mitoxantrone, etoposide, and cytarabine (MEC), a common chemotherapy regimen, in patients with R/R AML that expressed the CD30 marker. The authors found that the combination was safe and well tolerated. Future studies comparing this new combination with the use of MEC alone can help to inform its effectiveness for this patient population.